AES CORP. DL-,01/ US00130H1059 /
9/3/2024 8:02:00 AM | Chg. -0.0220 | Volume | Bid2:23:41 PM | Ask2:23:41 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
15.3000EUR | -0.14% | 0 Turnover: 0.0000 |
15.4060Bid Size: 2,000 | 15.4680Ask Size: 2,000 | 11 bill.EUR | - | - |
GlobeNewswire
8/30
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizu...
GlobeNewswire
8/28
Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Port...
Newsfile Corp
8/26
ALX Resources Corp. Completes Prospecting and Sampling Programs at the Cannon Copper Project, Ontari...
GlobeNewswire
8/22
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderat...
Newsfile Corp
8/20
Appia Confirms Outstanding Desorption Results From Its Ionic Adsorption Clay Targets Maia, Electra, ...
GlobeNewswire
8/15
Great Place To Work® Announces the 2024 Best Workplaces in Latin America Representing 3.8 Million Em...
GlobeNewswire
8/14
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic...
GlobeNewswire
8/14
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/12
Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib
GlobeNewswire
8/12
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at...
GlobeNewswire
8/8
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3...
GlobeNewswire
8/6
Paperclip Partners With Flying Cloud Technology, Premier Federal to Create Zero Trust Data Safe Plat...
GlobeNewswire
8/1
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficienc...
Newsfile Corp
7/30
Canter Resources Reports up to 840 ppm Lithium and 4,700 ppm Boron from Phase I Drilling at the Colu...
GlobeNewswire
7/24
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927...
GlobeNewswire
7/18
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at...